20 research outputs found

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

    Ultrastructure of anterior and mid-regions of infective juveniles of Steinernema feltiae

    No full text
    La rĂ©gion antĂ©rieure des juvĂ©niles infestants de troisiĂšme stade de #Steinernema feltiae$ consiste en une cavitĂ© buccale allongĂ©e soutenue par une invagination de la cuticule du corps et par certaines zones de la cuticule buccale. La cavitĂ© buccale est rĂ©trĂ©cie dans sa partie moyenne et Ă©largie postĂ©rieurement. La cavitĂ© buccale peut ĂȘtre divisĂ©e en sept rĂ©gions, la rĂ©gion 1 correspondant au cheilostome bordĂ© par la cutile du corps, la rĂ©gion 2 Ă©tant bordĂ©e par les cellules en arcade, les rĂ©gions 3 Ă  7 bordĂ©es par la cuticule et entourĂ©es par les cellules musculaires dĂ©signĂ©es comme M1 Ă  M5. Le corpus oesophagien consiste en une lumiĂšre triradiĂ©e soutenue par les myofilaments des cellules marginales et radiales. L'orifice de la glande dorsale est situĂ© Ă  la base de la cavitĂ© buccale tandis que ceux des glandes subventrales sont lĂ©gĂšrement antĂ©rieurs Ă  l'anneau nerveux. Le conduit cuticularisĂ© et les cellules de soutien de la glande sĂ©crĂ©trice/excrĂ©trice situĂ©e Ă  proximitĂ© de l'anneau nerveux s'Ă©tendant postĂ©rieurement et occupent la majeure partie de la cavitĂ© du corps au niveau de la valve oesophago-intestinale et de la rĂ©gion antĂ©rieure de l'intestin. Au centre du bulbe basal de l'oesophage, la lumiĂšre s'Ă©largit pour former la cavitĂ© de la "pompe", entourĂ©e par une cuticule rugueuse et denticulĂ©e soutenue par les cellules marginales et radiales. Les bactĂ©ries localisĂ©es entre la valve oesophago-intestinale et la rĂ©gion ventriculaire de l'intestin sont entourĂ©es de microvillositĂ©s. (RĂ©sumĂ© d'auteur
    corecore